Tata Group’s healthcare venture is said to have started initial discussions with Moderna Inc for a partnership to launch its COVID-19 vaccine in India, the Economic Times reported on Monday.
Tata Medical & Diagnostics could team up with the India’s Council of Scientific and Industrial Research to carry out clinical trials of Moderna’s vaccine candidate in India, the said, citing officials familiar with the matter.
Tata is likely to join hands with the Council of Scientific & Industrial Research (CSIR)—India’s premier research organization—to conduct clinical trials of Moderna’s vaccine candidate in India.
It is worth mentioning here that foreign vaccine makers must carry out a bridging trial on the Indian population in the country before rolling out their products. More importantly, if the vaccines are approved abroad, foreign companies must conduct phase-3 trials with volunteers in India.
In January 2020, the Coalition for Epidemic Preparedness Innovations (CEPI)—a part of the COVAX facility of the World Health Organization—provided funds to Moderna to develop its mRNA vaccine against the coronavirus. Plus, the COVAX facility wants to equitably distribute 200 crore Covid-19 vaccines in low-and middle-income countries including India by the end of 2021.